Skip to main content
Premium Trial:

Request an Annual Quote

Vizgen Launches With $14M Series A Financing

NEW YORK – Vizgen, a new startup in the spatial genomics field, said on Thursday that it has received $14 million in a Series A funding round led by Arch Venture Partners and Northpond Ventures.

In a statement, Cambridge, Massachusetts-based Vizgen said it would use the funds to accelerate commercialization of its patented "multiplexed error-robust fluorescence in situ hybridization" (MERFISH) platform. The technology enables spatially resolved, single-cell transcriptomics.

Xiaowei Zhuang, a Howard Hughes Medical Institute investigator, developed MERFISH in her lab at Harvard University with cofounder Jeffrey Moffitt, now a researcher at Boston Children's Hospital. Harvard's David Walt is also a cofounder and a member of the firm's board of directors.

"MERFISH is a game-changing technology in single-cell genomics and has broad applications in both fundamental biology and medicine," Walt, who also cofounded Illumina, Quanterix, and other firms, said in a statement. "Error detection and correction enable researchers to get the right answer. Vizgen's patented technology is critical for powering this unprecedented massively multiplexed single-molecule detection capability."

Northpond has recently participated in funding rounds for Inflammatix, IsoPlexis, Scipher, ChromaCode, SGI-DNA, SpeeDx, and Ultivue.

Arch Venture Partners also participated in Ultivue's Series C round. Over the last year, it also funded LunaPBC and One BioMed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.